Skip to content

Application of Oliceridine PCIA in Orthopedic Surgery

Application of Oliceridine PCIA in Orthopedic Surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093106
Enrollment
Unknown
Registered
2024-11-28
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative analgesia

Interventions

Standard sufentanil group:sufentanil PCIA
0 mg/h of oliceridine :Oliceridine PCIA, 0 mg/h
0.2 mg/h of oliceridine :Oliceridine PCIA, 0.2 mg/h
0.4 mg/h of oliceridine :Oliceridine PCIA, 0.4 mg/h

Sponsors

Affiliated Cancer Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Patients undergoing orthopedic surgery under elective general anesthesia; (2) Age: 18-68 years old; (3) ASA grades I-II; (4) BMI:18-30kg/m2.

Exclusion criteria

Exclusion criteria: (1) There were already other acute and chronic pains before the surgery; (2) Pregnancy, lactation, or planned pregnancy; (3) Suffering from mental and neurological disorders, chronic obstructive pulmonary disease or pulmonary heart disease, cardiovascular disease, etc; (4) Allergies or contraindications to anesthetics, adjunctive analgesics, salvage analgesics, antiemetic drugs, antibiotics used in the study; (5) Long term treatment with opioid drugs or use of any analgesic within 48 hours prior to surgery; (6) Suffering from sleep apnea syndrome; (7) For patients with contraindications to the investigational drug.

Design outcomes

Primary

MeasureTime frame
patient satisfaction after surgery;

Secondary

MeasureTime frame
analgesic condition;sedation condition;usage condition of analgesia pumps;adverse reactions;

Countries

China

Contacts

Public ContactSun Yalin

Affiliated Cancer Hospital of Zhengzhou University

suyalinbest@163.com+86 138 3838 6469

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026